The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Cytokinetics Inc (NASDAQ: CYTK) closed at $36.96 down -0.73% from its previous closing price of $37.23. In other words, the price has decreased by -$0.73 from its previous closing price. On the day, 1.3 million shares were traded. CYTK stock price reached its highest trading level at $38.03 during the session, while it also had its lowest trading level at $36.71.
Ratios:
For a deeper understanding of Cytokinetics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.99 and its Current Ratio is at 5.99.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on April 24, 2025, initiated with a Overweight rating and assigned the stock a target price of $55.
On February 07, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $86.
On January 22, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $80.Stifel initiated its Buy rating on January 22, 2025, with a $80 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 14 ’25 when Blum Robert I sold 5,000 shares for $38.15 per share. The transaction valued at 190,750 led to the insider holds 393,108 shares of the business.
FADY MALIK bought 14,000 shares of CYTK for $467,040 on Jul 08 ’25. On Jul 08 ’25, another insider, Malik Fady Ibraham, who serves as the EVP Research & Development of the company, sold 2,000 shares for $33.76 each. As a result, the insider received 67,520 and left with 140,610 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 4414021632 and an Enterprise Value of 3918114816. For the stock, the TTM Price-to-Sale (P/S) ratio is 229.66. Its current Enterprise Value per Revenue stands at 203.877 whereas that against EBITDA is -7.045.
Stock Price History:
The Beta on a monthly basis for CYTK is 0.64, which has changed by -0.35161966 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, CYTK has reached a high of $61.38, while it has fallen to a 52-week low of $29.31. The 50-Day Moving Average of the stock is 11.02%, while the 200-Day Moving Average is calculated to be -15.49%.
Shares Statistics:
For the past three months, CYTK has traded an average of 1.77M shares per day and 1549040 over the past ten days. A total of 119.22M shares are outstanding, with a floating share count of 116.79M. Insiders hold about 2.20% of the company’s shares, while institutions hold 116.10% stake in the company. Shares short for CYTK as of 1749772800 were 14005230 with a Short Ratio of 8.51, compared to 1747267200 on 15602822. Therefore, it implies a Short% of Shares Outstanding of 14005230 and a Short% of Float of 15.299999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
